Xeris (XERS) Q1 2026 Earnings Call Transcript

Xeris Biopharma reported Q1 total revenue of $83.1 million, up 38% year over year, with net product revenue rising 43% to $82.5 million and adjusted EBITDA improving to $15.1 million from a year ago. Recorlev was the standout, with revenue up 95% to $49.8 million, while the company raised full-year revenue guidance to $380 million-$390 million from $375 million-$390 million. Gvoke was flat at $20.8 million due to Medicare-related prescription weakness, but management said it expects recovery later in the year and remains on track to start the XP-8121 Phase III program later in 2026.

Analysis

This print is less about a one-quarter beat than about a change in operating regime: Xeris is now compounding from a bigger base while still funding a meaningful launch investment cycle. The key second-order effect is that Recorlev’s commercial expansion is now a lagged earnings driver, meaning the market is likely underestimating H2 acceleration if physician coverage and patient flow continue to scale with the expanded field force. That creates a setup where reported growth can stay strong even if near-term margin optics look slightly noisy.

The more interesting dynamic is capital allocation optionality. Once a specialty pharma company shows it can self-fund both a launch buildout and a Phase III asset, the equity story can re-rate from "single-product execution" to "platform with multiple shots on goal." That is typically where higher-quality pharma multiples expand, because investors begin discounting not just revenue growth but the probability of inorganic tuck-ins, portfolio broadening, and lower financing risk.

The main risk is that the current enthusiasm may be pulling forward too much of the Recorlev ramp before the expanded sales force fully matures. If prescription growth decelerates in late Q2 or early Q3, the stock could give back gains quickly because the valuation will be increasingly dependent on uninterrupted momentum. Gvoke is the other swing factor: management is treating the Medicare disruption as temporary, but if patient economics remain impaired into the back half, it becomes a credibility issue around the durability of the broader franchise.

Contrarian take: the market may be over-focusing on the quarter and underpricing the pipeline leverage. XP-8121 is still the underappreciated call option here, and the fact that management is sequencing commercial infrastructure before trial launch suggests they want a clean commercial story when data emerges. If that asset advances on time, the stock could trade on a much larger addressable opportunity than the current specialty-growth framing implies.

Key Decisions for Investors

• Long XERS into the next 2-3 quarters: favorable asymmetry if Recorlev H2 acceleration and XP-8121 milestones both hit; downside is a mid-teens multiple compression if momentum stalls.
• Buy XERS Jan-2027 call spreads to express upside with defined risk; use strikes that benefit from a re-rating into pipeline optionality rather than just near-term earnings beats.
• Pair trade: long XERS / short a slower-growth specialty pharma peer with weaker self-funded pipeline economics; thesis is XERS’ improving operating leverage and launch scalability should outpace the basket.
• Trim/add rule: add on any post-print consolidation if the stock digests the guidance raise without volume breakdown; reduce if Q2 prescription data shows Recorlev inflection is more modest than implied.
• Watch for a tactical short against XERS only if Gvoke weakness persists into the next two reporting periods; that would be the first credible evidence that the growth narrative is less diversified than advertised.